Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)
October 2020
in “
Research Square (Research Square)
”
Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.
Studysummary This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on researchsquare.com →